Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. (2nd May 2018)

• Record Type: Journal Article
• Authors: Morley, Kirsten C.; Baillie, Andrew; Fraser, Isabel; Furneaux-Bate, Ainsley; Dore, Glenys; Roberts, Michael; Abdalla, Ahmed; Phung, Nghi; Haber, Paul S.
• Is Part Of: British journal of psychiatry. Volume 212:Number 6(2018)
• Page Start: 362
• Page End: 369
• Publication Date: 2018-05-02
• Subjects: Psychiatry -- Periodicals; Psychology, Pathological -- Periodicals; 616.89005
• DOI: 10.1192/bjp.2018.13
• Languages: English
• ISSNs: 0007-1250

Abstract

Abstract : Background: There are no available medications for the management of alcohol dependence for patients with alcoholic liver disease (ALD). Aims: To conduct a multisite, double blind, placebo-controlled, randomised clinical trial of baclofen in the treatment of alcohol dependence, with or without liver disease (trial registration: ClinicalTrials.gov, NCT01711125). Method: Patients ( n = 104) were randomised to placebo, baclofen 30 mg/day or 75 mg/day for 12 weeks. Primary outcomes included survival time to lapse (any drinking), relapse (≥5 drinks per day in men and ≥4 in women), and the composite outcome of drinks per drinking day, number of heavy drinking days, and percentage days abstinent. Results: There was a significant effect of baclofen (composite groups) on time to lapse (χ 2 = 6.44, P <0.05, Cohen's d = 0.56) and relapse (χ 2 = 4.62, P <0.05, d = 0.52). A significant treatment effect of baclofen was observed for percentage days abstinent (placebo 43%, baclofen 30 mg 69%, baclofen 75 mg 65%; P <0.05). There was one serious adverse event (overdose) directly related to medication (75 mg). Conclusions: Baclofen may be an effective treatment option for patients with ALD. However, given the profile of adverse events, the role for this medication might be best limited to specialist services. Declaration of interest: None.